Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
News|Podcasts|August 7, 2026
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine why commercial readiness cannot wait until late-stage development, how operational trial infrastructure must precede AI optimization, and the execution gap between sponsor-built tools and site-level needs.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part three of her interview , Stella K. Vnook, CEO of Kaida BioPharma and founder of Aviva Ventures, makes the case that commercial strategy must now inform clinical development from the earliest stages. Indication selection, trial design, and endpoint choices all require commercial input upfront rather than being treated as development decisions subject to post-hoc commercialization planning. - In a
contributed article from Almac Clinical Technologies , authors examined why real-time AI-enabled decision-making only accelerates development when trials have coordinated operational infrastructure for randomization, supply management, and workflows capable of responding to new insights. The real readiness question is not whether sponsors have AI but whether their trial operating models can absorb faster information and respond in a controlled way without disrupting execution or compliance. - In the
pilot episode of Trial and Edit , we examined why sponsor-built AI tools are falling short at the site level, featuring insight from Abraham Gutman of AG Mednet, and an exclusive clip from Liz Beatty of Inato on what cross-asset site partnerships could mean for enrollment. The gap reflects a mismatch between sponsor-side optimization and site-side operational reality.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Trending on Applied Clinical Trials Online
1
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
2
What It Takes to Harmonize AI Across Fragmented Oncology Health Systems
3
Using AI to Design Better Trials Before the First Patient Enrolls: Q&A with Claire Riches, Citeline
4
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
5